A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival

Next Previous
Trial Profile

A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Dec 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Bevacizumab (Primary)
  • Indications Keratoplasty rejection
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 30 Nov 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
    • 03 Aug 2016 Planned End Date changed from 1 Sep 2017 to 1 Sep 2018.
    • 03 Aug 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top